We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Project POINT: Effectiveness and Scalability of an Overdose Survivor Intervention (POINT)

This study is not yet open for participant recruitment.
Verified November 2017 by Dennis Watson, Indiana University
Sponsor:
ClinicalTrials.gov Identifier:
NCT03336268
First Posted: November 8, 2017
Last Update Posted: November 9, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Information provided by (Responsible Party):
Dennis Watson, Indiana University
  Purpose

The investigators seek to assess the effectiveness of Project POINT (Planned Outreach, Intervention, Naloxone, and Treatment). Located in Indianapolis, Project POINT is a collaboration between Indianapolis Emergency Medical Services (EMS), the Eskenazi Emergency Department, Midtown Mental Health, and researchers at Indiana University. POINT is a quality improvement initiative that connects trained outreach workers with emergency department (ED) patients who experienced a non-fatal overdose. A member of the POINT team (a recovery coach or care coordinator with specialized training) meets patients after they have experienced an opioid overdose and, following a model of patient-centered care, offers them a range of evidence-based services including a brief assessment of high-risk behaviors, Hepatitis C and HIV testing, harm reduction counseling informed by motivational interviewing,and treatment referrals with follow-up to either a medication assisted treatment (MAT) provider, detoxification services, or an inpatient treatment setting

The primary goal of this project is the establishment of POINT as an effective and scalable intervention for engaging patients in MAT. This study employs a Hybrid Type 1 effectiveness implementation design to take full advantage of current POINT expansion efforts currently happening in Indiana.The goal of this pilot study is to replicate POINT in a new hospital and test its feasibility through (a) assessment of the chosen implementation strategy and (b) the testing of research protocols and secondary data collection procedures.


Condition Intervention
Substance Use Disorders Overdose Behavioral: POINT

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Supportive Care
Official Title: Project POINT: Effectiveness and Scalability of an Overdose Survivor Intervention

Further study details as provided by Dennis Watson, Indiana University:

Primary Outcome Measures:
  • Change in Duration of Medication Assisted Treatment (MAT) Engagement [ Time Frame: 3 years pre-enrollment through 6 & 12 months post-enrollment ]
    Change in duration of MAT engagement

  • Change in Frequency of Medication Assisted Treatment (MAT) Engagement [ Time Frame: 3 years pre-enrollment through 6 & 12 months post-enrollment ]
    Change in frequency of MAT engagement

  • Change in Frequency of Overdoses [ Time Frame: 3 years pre-enrollment through 6 & 12 months post-enrollment ]
    Change in the frequency of emergency department overdose admissions

  • Change in the Time to Relapse [ Time Frame: Enrollment through 6 & 12 months post-enrollment ]
    Changes in the duration of time before one experiences a relapse

  • Change in Hospital and Emergency Department Admissions [ Time Frame: 3 years pre-enrollment through 6 & 12 months post-enrollment ]
    Change in Hospital or Emergency Departments admissions (for any medical reason)

  • Change in Medicaid Enrollment [ Time Frame: Enrollment through 6 & 12 months post-enrollment ]
    Change in Medicaid enrollment (for those patients who are eligible and did not have insurance at ED admission)

  • Change in Child Welfare Involvement [ Time Frame: 3 years pre-enrollment through 6 & 12 months post-enrollment ]
    Change in Department of Child Services (DCS) involvement, including number of open cases and number of children in foster care

  • Change in Incarceration [ Time Frame: 3 years pre-enrollment through 6 & 12 months post-enrollment ]
    Change in the number of days one experienced incarceration (county jail and department of corrections)


Estimated Enrollment: 60
Anticipated Study Start Date: March 1, 2018
Estimated Study Completion Date: December 30, 2018
Estimated Primary Completion Date: August 1, 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: POINT
This arm will be offered both POINT services (in addition to standard emergency care) and enrollment in study data collection. If they choose to enroll in POINT, they may choose whether or not to enroll in data collection, as it is not required. Should they enroll in data collection, they will be consented and enrolled in the research study as a participant in the POINT study arm.
Behavioral: POINT
A recovery coach meets patients in the ED after they have been revived from an overdose to offer a range of services including an assessment of high-risk behaviors, Hep C/HIV testing, harm reduction counseling, and treatment referrals with follow-up to either a medication assisted treatment (MAT) provider, detoxification services, or an inpatient treatment setting. Patients are offered a take-home naloxone kit and assistance with Medicaid enrollment. Close collaboration with the local community mental health provider ensures POINT patients have their first assessment for MAT within 1-2 business days of ED discharge. Also, recovery coaches offer to accompany patients to intake appointments or criminal justice and child welfare meetings as part of the standard care they deliver.
No Intervention: Standard Care
This arm will only be offered enrollment in study data collection, as they will receive standard emergency care. If they choose to enroll, they will be consented in the research study as the Standard Care arm.

  Show Detailed Description

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Revived from a drug overdose
  • Arrived at the hospital during a time of day when we are enrolling patients in the study
  • Age 18 or older
  • Be medically stable (i.e., cleared to leave the ED by a physician) and capable of providing consent

(Individuals arriving during a POINT shift who do not wish to participate in the study are still eligible to receive POINT services.)

Exclusion Criteria:

  • Not in the ED for drug overdose
  • Not over age 18
  • Not considered to be medically stable and capable of providing consent they will be excluded from the study
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03336268


Contacts
Contact: Lisa Robison, MPH 317-278-0382 ldrobiso@imail.iu.edu

Sponsors and Collaborators
Indiana University
Investigators
Principal Investigator: Dennis P Watson, PhD Indiana University
  More Information

Responsible Party: Dennis Watson, Principal Investigator, Indiana University
ClinicalTrials.gov Identifier: NCT03336268     History of Changes
Other Study ID Numbers: 1706859955
First Submitted: October 26, 2017
First Posted: November 8, 2017
Last Update Posted: November 9, 2017
Last Verified: November 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Substance-Related Disorders
Drug Overdose
Chemically-Induced Disorders
Mental Disorders